Investigational study of an antiplatelet treatment for patients with NSTEMI or STEMI acute coronary syndromes

The purpose of this study is to determine the effectiveness of an experimental drug in stopping the formation of new blood clots in patients at risk of stroke or heart attack. Overall, 18,000 patients will be recruited for this study. At Rush University Medical Center, we expect to enroll approximately 10 patients.

You may be eligible for this study if you:

• Are 18 years of age or older
• Have non-ST or ST segment elevation ACS

You are not eligible for this study if you:

• Have active bleeding
• Have a low platelet count (thrombocytopenia)
• Are on kidney dialysis

This is a partial list of eligibility and exclusion criteria. To determine if you are eligible to participate, please call the contact phone number provided. If you choose to respond by e-mail, please refer to the title of the study in your correspondence.